Sign In
Buy APTO
$1.71
+0 (+0%)
At Close: Jul 25, 2025
Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting
01:10pm, Thursday, 03'rd Nov 2022 GlobeNewswire Inc.
Data for Tuspetinib (HM43239) and Luxeptinib Accepted for Poster Presentation Data for Tuspetinib (HM43239) and Luxeptinib Accepted for Poster Presentation
Aptose Biosciences Inc. (APTO) Q3 2022 Earnings Call Transcript
07:52pm, Tuesday, 01'st Nov 2022
Aptose Biosciences Inc. (NASDAQ:APTO ) Q3 2022 Results Conference Call November 1, 2022 5:00 PM ET Company Participants Susan Pietropaolo - Managing Director William Rice - Chairman, President and CEO
Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022
08:01pm, Tuesday, 18'th Oct 2022 GlobeNewswire Inc.
SAN DIEGO and TORONTO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral kinase i
Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022
04:01pm, Tuesday, 18'th Oct 2022
SAN DIEGO and TORONTO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral kinase inh
Deciphera (DCPH) Rises 90% in the Past 6 Months: Here's Why
02:20pm, Friday, 30'th Sep 2022 Zacks Investment Research
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.
Horizon (HZNP) Completes Enrollment in Phase IV TED Study
12:59pm, Friday, 30'th Sep 2022 Zacks Investment Research
Horizon (HZNP) completes enrollment in the phase IV study evaluating Tepezza for the treatment of thyroid eye disease in patients with a low clinical activity score.
Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis
03:09pm, Thursday, 29'th Sep 2022 Zacks Investment Research
The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.
Merck's (MRK) Keytruda Gets Four New Approvals in Japan
05:47pm, Wednesday, 28'th Sep 2022 Zacks Investment Research
The Ministry of Health, Labour and Welfare approves Merck's (MRK) anti-PD-1 therapy, Keytruda, for four new cancer indications in Japan.
Seagen (SGEN) Inks Deal With LAVA Therapeutics for LAVA-1223
03:44pm, Tuesday, 27'th Sep 2022 Zacks Investment Research
Seagen (SGEN) signs an exclusive agreement with LAVA Therapeutics to develop and commercialize the latter's preclinical asset, LAVA-1223, targeting EGFR-expressing solid tumors.
Emergent (EBS) Acquires Worldwide Rights to Smallpox Antiviral
02:13pm, Tuesday, 27'th Sep 2022 Zacks Investment Research
Emergent (EBS) completes the acquisition of worldwide rights to Tembexa, an FDA-approved smallpox oral antiviral for all ages, from Chimerix.
Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study
02:50pm, Thursday, 22'nd Sep 2022 Zacks Investment Research
Evaxion (EVAX) enrolls the first patient in the phase IIb study evaluating its cancer therapy, EVX-01 in combination with Keytruda, for treating melanoma.
Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod
10:32pm, Wednesday, 21'st Sep 2022 Zacks Investment Research
The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.
Pacira (PCRX) Gets Positive CHMP View on Exparel Label Expansion
10:04pm, Wednesday, 21'st Sep 2022 Zacks Investment Research
The CHMP gives a positive opinion on Pacira's (PCRX) marketed drug Exparel and recommended a marketing authorization for the product to treat postsurgical pain in children aged six years or older.
Seagen's (SGEN) Tukysa Gets FDA Priority Review for New Indication
01:49pm, Tuesday, 20'th Sep 2022 Zacks Investment Research
FDA grants priority review to Seagen's (SGEN) sNDA for Tukysa in combination with trastuzumab for previously treated HER2-positive metastatic colorectal cancer. A decision is due on Jan 19, 2023.
Roche's (RHHBY) Vabysmo Gets Approval for nAMD & DME in Europe
04:28pm, Monday, 19'th Sep 2022 Zacks Investment Research
The European Commission approves Roche's (RHHBY) Vabysmo for treating neovascular or wet age-related macular degeneration and visual impairment due to diabetic macular edema.
